Möchten Sie immer auf dem neuesten Stand bleiben?

Therini Bio doses first patients in Ph1b trial evaluating novel anti-inflammatory therapy, THN391, in DME, and advances fibrin/VEGF bispecific THN622

ASHEVILLE, N.C., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Aeroflow Health, a pioneering healthcare company that leverages cutting-edge technology to support the delivery of medical products and services,...

ASHEVILLE, N.C., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Aeroflow Health, a pioneering healthcare company that leverages cutting-edge technology to support the delivery of medical products and services,...

ASHEVILLE, N.C., Jan. 14, 2026 (GLOBE NEWSWIRE) -- Aeroflow Health, a pioneering healthcare company that leverages cutting-edge technology to support the delivery of medical products and services,...

ASHEVILLE, N.C., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Aeroflow Urology, a nationwide provider of continence care supplies through insurance and a division of Aeroflow Health, announced donations...

ASHEVILLE, N.C., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Aeroflow Health, a pioneering healthcare company that leverages cutting-edge technology to support the delivery of medical products and services,...

ANN ARBOR, Mich., Nov. 10, 2025 (GLOBE NEWSWIRE) -- ONL Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal...

ASHEVILLE, N.C., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Aeroflow Sleep, a national durable medical equipment (DME) provider specializing in CPAP supplies, today announced the results of a proprietary...

Exton, Pennsylvania, July 10, 2025 (GLOBE NEWSWIRE) -- Recently released research from Spherix Global Insights provides a timely look at the increasingly competitive and complex treatment landscape...

Therini Bio raised a $39M Series A financing, bringing the Series A total to $75M, from top-tier investors to commence THN391 Ph 1b AD and DME studies